ARWR compared with GPCR: revenue, margins and what each company keeps, and the suppliers and customers both name

ARWRArrowhead Pharmaceuticals, Inc.

Mkt capRevenueRevenue

GPCRStructure Therapeutics Inc.

Mkt capRevenueRevenue

Compare

ARWRArrowhead Pharmaceuticals, Inc.

GPCRStructure Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ARWR

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±8.5%▼−2.99%×0.35

Q2 FY26±7.3%▼−6.75%×0.93

Q1 FY26±11.4%▼−0.19%×0.02

Nov 26 '25±13.6%▲+23.34%×1.71

GPCR

No earnings history for GPCR.

= impliedARWR realized, solidGPCR realized, hatchedOne scale, both sides: full bar = 24%× = |realized| ÷ impliedSource: market data

ARWRArrowhead Pharmaceuticals, Inc.

60.490.00%· post 59.64

Mkt cap$8.5BRevenue$75MQ3 FY26Revenue$829MFY25

GPCRStructure Therapeutics Inc.

21.89▼−0.22%· post 22.41

ClosedOct 30 '26

Mkt cap$4.8BRevenue—Revenue—

Compare

ClosedOct 30 '26

ARWRArrowhead Pharmaceuticals, Inc.

GPCRStructure Therapeutics Inc.

60.490.00%post 59.64

Price

21.89▼−0.22%post 22.41

$8.5B

Mkt cap

$4.8B

Q3 FY26$75M

Revenue

—

FY25$829M

Revenue

—

ARWR60.490.00%vsGPCR21.89▼−0.22%ClosedOct 30 '26